Literature DB >> 8950760

Standardized mitotic counts in breast cancer. Evaluation of the method.

Y U Collan1, T Kuopio, J P Baak, R Becker, W V Bogomoletz, M Deverell, P van Diest, C van Galen, K Gilchrist, A Javed, V M Kosma, H Kujari, P Luzi, G M Mariuzzi, E Matze, R Montironi, M Scarpelli, D Sierra, S Sisti, S Toikkanen, P Tosi, W F Whimster, E Wisse.   

Abstract

Twenty-one pathologists and technicians participated in a study evaluating the variation present in mitotic counts for prognostication of breast cancer. The participants counted the mitotic figures in 20 breast cancer samples from ten high power fields (mitotic activity index, MAI, giving the results in mitotic figures per 10 fields) and also made a correction for field size and area fraction of the neoplastic epithelium to get the standardized mitotic index (volume fraction corrected mitotic index, or M/VV index, giving the result in mitotic figures per square mm of neoplastic epithelium). The difference in variation between the two methods was not big, but the standardized mitotic index (SMI) showed consistently smaller variation among all participants and different subgroups. Experienced pathologists had the highest variation in mitotic counts, and specially trained technicians, the lowest. The efficiency of the mitotic counts in grading (the grading efficiency) was used to evaluate the mitotic counts. In groups without special training for mitotic counts the mean grading efficiency was lower (experienced and training pathologists both on average had the potential to grade 88% of the cases correctly) than in the group specially trained for the purpose (trained technicians had the potential to grade 95% of the cases correctly). Among the specially trained technicians, the grading efficiency was of the same magnitude as the grading efficiency achieved in determining the S-Phase fraction of cells from paraffin embedded breast cancers by flow cytometry in different laboratories. The results suggest that special training is helpful in making mitotic counts more reproducible, and that in trained hands, the mitotic counts give results comparable to more sophisticated methods of determining proliferative activity in breast cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8950760     DOI: 10.1016/S0344-0338(96)80075-6

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

Review 2.  Biomolecular features of clinical relevance in breast cancer.

Authors:  Maria Grazia Daidone; Angelo Paradiso; Massimo Gion; Nadia Harbeck; Fred Sweep; Manfred Schmitt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-17       Impact factor: 9.236

3.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

4.  Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma.

Authors:  H Imamura; S Haga; T Shimizu; O Watanabe; T Kajiwara; M Aiba
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

5.  Screen-detected breast cancers have a lower mitotic activity index.

Authors:  R P Groenendijk; P Bult; L Tewarie; P G Peer; R F van der Sluis; T J Ruers; T Wobbes
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer.

Authors:  P Kronqvist; T Kuopio; P Jalava; Y Collan
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

7.  Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.

Authors:  J M Karjalainen; M J Eskelinen; S Nordling; P K Lipponen; E M Alhava; V M Kosma
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  Proliferative activity in Libyan breast cancer with comparison to European and Central African patients.

Authors:  Jamela Boder; Fathi Abdalla; Mohamed Elfagieh; Abdelbaset Buhmeida; Yrjö Collan
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.